Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.63−0.05 (-7.21%)
Close on Nov 17, 2026Market cap $23.84MP/E –Yield –
Metagenomi Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Metagenomi Therapeutics's profit margin for the twelve months ending Mar 31, 2026 was -384.6%. For fiscal 2025 it was -348.5%, against -149.3% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -348.5% | −199.3 |
| FY2024 | Dec 31, 2024 | -149.3% | +3.2 |
| FY2023 | Dec 31, 2023 | -152.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -1847.7% | −1241.0 |
| Q4 FY2025 | Dec 31, 2025 | -576.0% | −332.6 |
| Q3 FY2025 | Sep 30, 2025 | -235.5% | −72.5 |
| Q2 FY2025 | Jun 30, 2025 | -233.9% | −180.2 |
| Q1 FY2025 | Mar 31, 2025 | -606.7% | −381.4 |
| Q4 FY2024 | Dec 31, 2024 | -243.4% | −87.8 |
| Q3 FY2024 | Sep 30, 2024 | -163.0% | −2.7 |
| Q2 FY2024 | Jun 30, 2024 | -53.7% | +61.1 |
| Q1 FY2024 | Mar 31, 2024 | -225.4% | −39.0 |
| Q4 FY2023 | Dec 31, 2023 | -155.6% | – |
| Q3 FY2023 | Sep 30, 2023 | -160.3% | – |
| Q2 FY2023 | Jun 30, 2023 | -114.7% | – |
| Q1 FY2023 | Mar 31, 2023 | -186.4% | – |
See a number that looks wrong?